Drugs / S1 [arm: experimental] — S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
S1 [arm: experimental] — S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04819971 | Dec 2021 → Dec 2025 | gastric cancer | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S1 [arm: experimental] — S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04819971 ↗ |
| Route | Oral | “S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle” NCT04819971 ↗ |